Shikari® Anti-Tocilizumab ELISA Kit

$1,285.00

The Shikari® Anti-Tocilizumab ELISA Kit is intended for the quantitative determination of tocilizumab in serum and plasma samples. The Shikari® Anti-Tocilizumab ELISA Kit is Research Use Only and not for diagnostic procedures.

SKU: TOC-QNS-ACT Category: Tags: , , ,

Anti-Tocilizumab antibodies are immunogenic responses produced by the host immune system against Tocilizumab, a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor. Tocilizumab is widely used for treating chronic inflammatory autoimmune conditions such as rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (soJIA), Crohn’s disease (CD), systemic lupus erythematosus (SLE), vasculitis, and giant cell arteritis. However, the formation of anti-drug antibodies (ADAs), particularly neutralizing antibodies, may affect drug efficacy by inhibiting receptor binding or altering pharmacokinetics.

Monitoring for anti-Tocilizumab antibodies is essential in clinical settings to assess reduced therapeutic response, unexplained disease flare-ups, or altered drug clearance. The detection of these antibodies—through assays such as bridging ELISAs or neutralizing antibody assays—can inform clinicians whether immune-mediated loss of drug effectiveness is occurring. Persistent or high-titer anti-Tocilizumab responses may necessitate changes in dosing strategies, immunosuppressive co-medications, or even transitioning to alternative biologic therapies.

In research, anti-Tocilizumab antibody studies contribute to the understanding of immunogenicity patterns in biologic treatments. Data gathered through clinical trials and post-marketing surveillance supports the refinement of therapeutic regimens and development of less immunogenic formulations. Furthermore, insights into patient-specific immunogenic responses may improve stratification methods and personalize treatment plans for autoimmune and inflammatory disorders.

This product is manufactured in Turkey by Matriks Biotek.

Size 1 x 96 Well
Sensitivity 5 ng/mL
Dynamic Range 10 – 160 ng/mL
Incubation Time 140 minutes
Sample Type Serum, Plasma
Immunogen
Source Species
Specificity
Expression System
Clone
Group
Alpha Chain
Beta Chain
Peptide
Peptide Source
Format
Buffer
Concentration
Storage 2-8°C
Alternative Names Anti-Tocilizumab antibodies, Tocilizumab ADA, Tocilizumab-binding antibodies, Anti-IL-6R monoclonal antibody antibodies, Tocilizumab-specific immunoglobulins, Human anti-humanized IL-6 receptor antibody, Anti-TCZ IgG, Tocilizumab-neutralizing antibodies, Anti-actemra antibodies, Tocilizumab immune response markers.
Instructions For Use https://eaglebio.com/wp-content/uploads/2025/06/TOC-QNS-ACT-shikari-anti-tocilizumab-elisa-instructions-for-use.pdf
MSDS https://eaglebio.com/wp-content/uploads/2025/06/TOC-QNS-ACT-shikari-anti-tocilizumab-elisa-safety-data-sheet-sds.pdf

Product Citations